The Pakistan Young Pharmacist Association (PYPA) has formally urged Prime Minister Shehbaz Sharif to reinstate government-controlled drug pricing, as soaring market rates are making essential medicines virtually unaffordable for many.

According to PYPA, life-saving medications that government hospitals purchase at regulated rates are being sold in the private market at nearly 40 times higher. Examples include Montelukast, priced at Rs 3.07 by provincial procurement but sold for over Rs 93, and Omeprazole 20 mg, fixed at Rs 1.70 yet retailing at Rs 67.85.

The pharmacists emphasized that the government-administered price list—designed for public sector use—should be extended to general consumers to protect affordability and clarity in pricing. They warned that unchecked pricing adjustments are fueling a healthcare affordability crisis.

Healthcare professionals and watchdogs report that deregulation of non-essential drug pricing has unleashed unchecked increases—some drugs have doubled or tripled in price within months. Industry stakeholders warn this model favors corporate profit over patient access.

Policy experts and DRAP insiders echo the call for immediate action. The regulator has ordered a nationwide survey to assess the extent of price hikes; findings may lead to reinstating regulated pricing or introducing tiered price controls for vulnerable drug categories.

As survey results emerge, the debate centers on restoring regulatory oversight while balancing manufacturer sustainability. Advocates argue that bringing back comprehensive medicine pricing policy is critical to ensuring fair access to quality pharmaceuticals across Pakistan.